article thumbnail

Opinion: STAT+: There’s a better way to get drugs on the market: progressive approval

STAT

The public and pharmaceutical companies are calling for changes in drug regulation and the costs of medicines. Companies want to see products approved faster for financial reasons, and patients want medicines that can improve their lives. They are right to do so.

article thumbnail

STAT+: U.K. pharma increasingly violates voluntary industry marketing codes, and probes are taking longer

STAT

Pharmaceutical companies in the U.K. Between 2004 to 2021, the Prescription Medicines Code of Practice Authority, a self-regulatory body overseen by the Association of the British Pharmaceutical Industry, ruled on more than 1,100 cases involving nearly 160 companies where there was a breach of the industry code.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

STAT

German pharmaceutical company Bayer is expanding its U.S. Bayer’s C-suite has been on a soul-searching mission for the last year, spurred by new leadership and the realization that the company is, as new CEO Bill Anderson said earlier this month, “ badly broken.

article thumbnail

Lupin acquires anti-diabetes trademarks from Boehringer Ingelheim to strengthen portfolio

Express Pharma

On December 13, 2024, Lupin, a global pharmaceutical company, announced the acquisition of anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim International GmbH. The move is aimed at strengthening Lupins diabetes portfolio in India.

Diabetes 105
article thumbnail

The rise of Fixed-Dose Combinations (FDCs): What it means for pharma players

Express Pharma

Additionally, pharmaceutical companies have increasingly turned to FDCs as a way to differentiate their products in a highly competitive market. By introducing unique formulations that combine existing drugs, companies can extend product life cycles and maintain exclusivity over certain combinations.

article thumbnail

Pharmaceutical training boost: how the growth and skills levy could shape industry development

European Pharmaceutical Review

While this investment led to a seven percent rise in annual apprenticeship starts within the life sciences sector between 2018/19 and 2022/23, industry leaders have consistently argued that the narrow focus on apprenticeships left gaps in training provision. billion in 2017/18 to 2.5 billion in 2023/24.

article thumbnail

Lupin partners with Celnova Pharma to distribute NaMuscla in Argentina and Colombia

Express Pharma

Global pharmaceutical company Lupin has announced that its subsidiary, Lupin Atlantis Holdings SA, has entered into a distribution agreement with Celnova Pharma for Lupin’s orphan drug, NaMuscla (mexiletine). 18 December 2018 Emery AEH, Neuromuscular Discord 1991;1:19-29 Trivedi JR, et al. References: Vicart S, et al.